HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

The Growing Burden of ABSSSI

Bruce Jones, PharmD, BCPS, discusses the growing burden of ABSSSI and why there have been an influx of MRSA cases.

Segment Description: Bruce Jones, PharmD, BCPS, clinical pharmacy specialist, infectious disease, St. Joseph’s/Candler Health System, discusses the growing burden of ABSSSI and why there have been an influx of MRSA cases.

Interview Transcript (modified slightly for readability):

“I think acute bacterial skin and skin structure infections (ABSSSI) is something we are all dealing with and the issue is with patients being hospitalized. We’re seeing greater than 3 million emergency department visits on a given year. Many of these patients are being treated as outpatients but more and more we’re seeing linear growth of how many are being treated as in-patients.

What we see with ABSSSI is mainly Gram-positive in nature; you know, Streptococcus, Staphylococcus. I think the big worry for us is Staphylococcus aureus, specifically methicillin-resistant Staphylococcus aureus (MRSA); it’s becoming more and more difficult to treat. We’re seeing more issues with certain first-line antibiotics, so that’s probably our biggest issue we currently deal with right now, the MRSA-specific patients.

I think we’re seeing an increase [in ABSSSI cases], you know we can look to our local antibiogram, and we’re seeing more and more MRSA patients. We’re doing a better job at diagnosing them—I think that’s part of it—and we’re seeing a lot more recurrence as well. And so, as these become harder and harder to treat, it’s a bigger burden on us and health care systems.”